Close
  Indian J Med Microbiol
 

Figure 5: (A) In vitro drug release profile, (B) in vivo pharmacokinetic study of FSM; FSM-PLGA-NP, FSM-chi-coated- PLGA-NP, and FSM-chi-conj. PLGA-NP after i.v. injection at an equivalent FSM dose of 6.6 mg/kg. (C) Typical chromatogram, plotted as absorbance (276 nm) vs. elution time, showing the separation and detection of FSM and the internal standard; retention times (min) are 8.275 for FSM and 10.059 for p-nitrophenol. FSM, furosemide; PLGA, Poly (lactide-co-glycolide); FSM-PLGA-NP, FSM loaded PLGA nanoparticle; FSM-chi-coated-PLGA-NP, FSM loaded chitosan-coated PLGA; (FSM-chi-conj. PLGA-NP, FSM loaded chitosan-conjugated PLGA nanoparticle.

Figure 5: (A) <i>In vitro</i> drug release profile, (B) <i>in vivo</i> pharmacokinetic study of FSM; FSM-PLGA-NP, FSM-chi-coated- PLGA-NP, and FSM-chi-conj. PLGA-NP after <i>i.v</i>. injection at an equivalent FSM dose of 6.6 mg/kg. (C) Typical chromatogram, plotted as absorbance (276 nm) <i>vs</i>. elution time, showing the separation and detection of FSM and the internal standard; retention times (min) are 8.275 for FSM and 10.059 for p-nitrophenol. FSM, furosemide; PLGA, Poly (lactide-co-glycolide); FSM-PLGA-NP, FSM loaded PLGA nanoparticle; FSM-chi-coated-PLGA-NP, FSM loaded chitosan-coated PLGA; (FSM-chi-conj. PLGA-NP, FSM loaded chitosan-conjugated PLGA nanoparticle.